Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. is asking stockholders to vote at its June 22, 2026 virtual annual meeting on director elections, auditor ratification, a significant warrant-related share issuance and a new equity incentive plan.
Proposal 3 seeks approval, for Nasdaq Listing Rule 5635(d) purposes, for up to 2,272,728 shares of common stock from March 2026 investor warrants and up to 159,091 shares from placement agent warrants, both tied to a prior financing. Proposal 4 would adopt the 2026 Equity and Incentive Compensation Plan with 2,000,000 new shares plus 339,199 remaining from the 2022 plan and an annual “evergreen” increase of up to 4% of shares outstanding through 2036, which could raise fully diluted overhang from 10.7% to 33.5%.
The company also outlines voting mechanics, including 5,208,915 common shares (one vote each) and 125 shares of Series C Preferred Stock with 13,000 votes per share, and the Board’s plan to cast 1,625,000 votes (about 24% of total voting power) in favor of all proposals under an irrevocable proxy.
FibroBiologics, Inc. reported that its Chief Executive Officer, O'HEERON PETE, received a grant of stock options. The award covers 92,410 options to buy common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the vesting schedule, one quarter of the option shares will vest on the one-year anniversary of the May 4, 2026 grant date. The remaining shares will vest in 36 equal monthly installments, provided the CEO remains in continuous service. Following this grant, the filing shows 92,410 derivative securities held directly.
FibroBiologics, Inc. reported that its Chief Executive Officer, O'HEERON PETE, received a grant of stock options. The award covers 92,410 options to buy common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the vesting schedule, one quarter of the option shares will vest on the one-year anniversary of the May 4, 2026 grant date. The remaining shares will vest in 36 equal monthly installments, provided the CEO remains in continuous service. Following this grant, the filing shows 92,410 derivative securities held directly.
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.
FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share. The options expire on May 4, 2036 and represent a compensation award, not an open-market trade.
According to the vesting terms, one quarter of the option shares will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments as long as Davis remains in continuous service. Following this grant, he holds 61,607 stock options directly.
FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share. The options expire on May 4, 2036 and represent a compensation award, not an open-market trade.
According to the vesting terms, one quarter of the option shares will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments as long as Davis remains in continuous service. Following this grant, he holds 61,607 stock options directly.
FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia. On May 4, 2026, he was granted a stock option covering 61,607 shares of common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the filing, one quarter of the option will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, assuming he remains in continuous service. Following this grant, his reported derivative holdings consist of options for 61,607 underlying shares.
FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia. On May 4, 2026, he was granted a stock option covering 61,607 shares of common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the filing, one quarter of the option will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, assuming he remains in continuous service. Following this grant, his reported derivative holdings consist of options for 61,607 underlying shares.
FibroBiologics is offering up to $6,150,000 of its common stock in an at‑the‑market offering under a Sales Agreement with H.C. Wainwright & Co., allowing sales from time to time on Nasdaq at prevailing market prices. The company completed a 1-for-20 reverse stock split effective March 30, 2026, and reported 5,208,915 shares outstanding prior to this offering. The Sales Agreement pays a 3.0% sales commission to Wainwright; net proceeds, timing and the number of shares sold will vary with market prices. The prospectus notes the company’s public float calculation and Nasdaq listing compliance steps and discloses that the April registered offering generated approximately $2.5M in net proceeds.
FibroBiologics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC allowing it to sell shares of common stock with an aggregate offering price of up to $6,150,000 from time to time. Any net proceeds are expected to be used for working capital and general corporate purposes.
The Sales Agent will conduct sales as at-the-market offerings under an existing shelf registration statement on Form S-3 and a related prospectus supplement. FibroBiologics will pay a 3.0% commission on gross proceeds and reimburse specified legal and due diligence expenses. The company is not obligated to sell any shares and the ATM program can end once all authorized shares are sold or the agreement is terminated.
FibroBiologics, Inc. (FBLG) reported another quarterly loss as it funds multiple fibroblast-based cell therapy programs. For the three months ended March 31, 2026, the company recorded a net loss of $5.0 million, similar to the prior year period, as operating expenses rose to $5.1 million. Research and development spending increased to $3.0 million, reflecting preparation for clinical trials, while general and administrative costs declined to $2.1 million.
Cash and cash equivalents fell to $1.5 million as of March 31, 2026, from $4.9 million at year-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. To help fund operations, FibroBiologics used its standby equity purchase agreement to sell 133,108 shares for about $0.7 million in March and later completed an April registered offering that raised approximately $2.5 million net.
The company executed a 1-for-20 reverse stock split on March 30, 2026, leaving 5,208,915 common shares outstanding as of April 30, 2026. FibroBiologics continues to advance several programs, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell™ for degenerative disc disease, but it has not yet generated revenue. Management also reported a material weakness in internal control over financial reporting related to segregation of duties and plans to add accounting staff and strengthen controls.
FibroBiologics, Inc. (FBLG) reported another quarterly loss as it funds multiple fibroblast-based cell therapy programs. For the three months ended March 31, 2026, the company recorded a net loss of $5.0 million, similar to the prior year period, as operating expenses rose to $5.1 million. Research and development spending increased to $3.0 million, reflecting preparation for clinical trials, while general and administrative costs declined to $2.1 million.
Cash and cash equivalents fell to $1.5 million as of March 31, 2026, from $4.9 million at year-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. To help fund operations, FibroBiologics used its standby equity purchase agreement to sell 133,108 shares for about $0.7 million in March and later completed an April registered offering that raised approximately $2.5 million net.
The company executed a 1-for-20 reverse stock split on March 30, 2026, leaving 5,208,915 common shares outstanding as of April 30, 2026. FibroBiologics continues to advance several programs, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell™ for degenerative disc disease, but it has not yet generated revenue. Management also reported a material weakness in internal control over financial reporting related to segregation of duties and plans to add accounting staff and strengthen controls.
FibroBiologics, Inc. is soliciting votes at its virtual Annual Meeting on June 22, 2026 on director elections, auditor ratification, Nasdaq approval for certain March 2026 warrant issuances, and adoption of a new 2026 Equity and Incentive Compensation Plan. The board recommends FOR on all proposals and discloses that 125 shares of Series C Preferred Stock (held by the CEO) carry super‑voting rights totaling 1,625,000 votes the board will cast via an irrevocable proxy. The proxy materials state there were 5,208,915 shares of common stock outstanding as of April 24, 2026. The March Offering included warrants that could convert into up to 2,272,728 shares (exercise price $1.32) and placement agent warrants for up to 159,091 shares (exercise price $1.65), for which shareholder approval under Nasdaq Rule 5635(d) is being requested.
FibroBiologics, Inc. has received formal confirmation from Nasdaq that it now meets all requirements for continued listing on The Nasdaq Capital Market. Nasdaq verified compliance with both the $2.5 million stockholders’ equity requirement and the $1.00 bid price requirement, closing the previously disclosed listing matter.
The company’s common stock will continue trading under the symbol FBLG, but Nasdaq will apply one-year Mandatory Panel Monitor periods for both equity and bid price tests. If FibroBiologics falls out of compliance during these periods, Nasdaq staff would move directly to a delisting determination, though the company could request a new hearing to temporarily stay any delisting action.